At that point, assuming we like the way its coming together, we negotiate a pre-defined exit path for a possible investment: upon successful completion of XYZ clinical study, the Pharma will buyout the asset-centric entity in an upfront plus milestones type transaction.
This says something: even though a stateless network cannot absolutely make guarantees on delivery or completion of its task or even the path it may take, this downside is overcome by the sheer scalability and flexibility of this model over stateful systems.